One example specific for cancer cachexia is the anti-myostatin antibody landogrozumab, which progressed to a Phase II trial in pancreatic cancer patients; although, it was not considered to be superior to placebo in improving outcome measures related to muscle wasting [95]. The gene discussed is MSTN; the disease is cancer.